⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MESO News
Mesoblast Limited American Depositary Shares
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
prnewswire.com
FBLG
MESO
LGVN
FATE
Ryoncil® Profits Underpinning Substantial Growth Pipeline
globenewswire.com
MESO
Mesoblast Financial Results and Corporate Update Webcast
globenewswire.com
MESO
Stem Cell Therapy Market to Reach USD 45.2B by 2036 (8.4% CAGR) | U.S., Germany & Japan Lead Growth | Mesenchymal Stem Cells Hold 45% Share -- Future Market Insights
prnewswire.com
MESO
GERN
BCDA
NVS
BMY
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
globenewswire.com
MESO
Ryoncil® Net Revenues Increase for the Quarter to US$30M
globenewswire.com
MESO
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
globenewswire.com
MESO
FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
globenewswire.com
MESO
Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
globenewswire.com
MESO
Mesoblast Announces Changes to Board of Directors' Leadership Roles
globenewswire.com
MESO